FDA biologics center tries to calm waters after leadership turmoil

Karim Mikhail took over as acting director of the FDA's Center for Biologics Evaluation and Research (CBER), which regulates everything from vaccines to gene therapies. He's got his work cut out for him, aiming to boost staff morale and revisit some of his predecessor's controversial decisions. This could impact timelines for new biological products hitting the market.